Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
406 Index<br />
single-chain Fvs (scFvs), immunotoxins 355ff.<br />
single-chain IL-12 340<br />
Smad proteins 121<br />
solid tumors<br />
±, clinical trials 191<br />
±, immunotoxin therapy 360f.<br />
somatic hypermutation 363<br />
splice variants of genes, for encoding<br />
antigens 22<br />
SSX gene 21<br />
STAT see signal transducers <strong>and</strong> activation of<br />
transcription<br />
stem-cell transplantation (SCT) 197, 306<br />
stem cells, dendritic cells 183f.<br />
stressful death, tumor cell killing 218<br />
subdominant epitopes 211<br />
±, definition 224<br />
suicide gene strategy, BMT 304<br />
suppression<br />
±, immuno 107, 119±154<br />
±, of IL-10 129<br />
surveillance, immune 40, 65f., 230<br />
survivin 11<br />
synovial sarcomas, SSX gene 21<br />
systemic effects, IL-10 163<br />
t<br />
T-B cell collaboration 233<br />
T body approach, cancer immunotherapy<br />
287±298<br />
T cell anergy, effects of IL-10 127<br />
T cell apoptosis, effects of TGF-b 123<br />
T cell epitopes, universal tumor associated<br />
3±16<br />
T cell immunology<br />
±, reverse 17, 24<br />
T cell leukemias 347, 362<br />
T cell receptor (TCR) 99f., 210±214<br />
±, immunocytokines 331<br />
±, T-body approach 287, 290<br />
T cells<br />
±, gd 129<br />
±, antigen presentation 210f.<br />
±, antigen-specific responses 3<br />
±, autoimmunity 215ff.<br />
±, bacterial immunotherapy 275<br />
±, CD4 79, 81ff.<br />
±, effects of IL-10 159f.<br />
±, GvHD 303<br />
±, hybrid cell vaccination (HCV) 231±241<br />
±, immunocytokines 311±342<br />
±, in tumor immunity 40±55<br />
±, thymic 263<br />
±, thymic selection 206f.<br />
±, tumor cell killing 218±221<br />
±, tumor microenvironment 99ff., 114<br />
±, with surface CRs 287±298<br />
±, see also T lymphocytes<br />
T helper cells 233<br />
±, HCV 236f.<br />
±, immunocytokines 324<br />
±, immunotoxins 367<br />
T helper lymphocytes 18<br />
T immunotherapy, adoptive 5<br />
T lymphocyte apoptosis 111<br />
T lymphocytes 3<br />
±, effects of IL-10 126f.<br />
±, effects of polyamines 134<br />
±, effects of prostagl<strong>and</strong>in (PG) E2 131<br />
±, effects of TGF-b 122f.<br />
±, see also T cells<br />
T-T cell collaboration 233f.<br />
TAAs see tumor-associated antigens<br />
TADC see tumor-associated DC<br />
TAM see tumor-associated macrophages<br />
TAP see transporter associated with antigen<br />
processing<br />
TAP vaccines 77<br />
tapasin 71<br />
targeted cancer therapy 347f.<br />
targeting moiety, immunotoxins 348,<br />
354±357, 363±369<br />
TATC see tumor associated T cells<br />
TCR see T cell receptor<br />
telomerase, COX inhibitors 132<br />
tertiary lymphoid tissue 333<br />
tetramers, CTL monitoring 45<br />
TGF see transforming growth factor<br />
TGF-b, FasL 112<br />
therapeutic vaccination 5<br />
therapy<br />
±, adoptive transfer 41<br />
±, chemo- 299<br />
±, effects of IL-10 128f., 167<br />
±, implication of polyamine inhibition 134<br />
±, implication of prostagl<strong>and</strong>in (PG) E2<br />
inhibition 132<br />
±, implication of TGF-b inhibition 124f.<br />
±, MIF neutralization 130<br />
±, radio- 299<br />
±, thermo- 261<br />
thermotherapy, <strong>and</strong> HSPs 261<br />
three-cell interaction, HCV 234<br />
thymic selection of T cells 206f.<br />
thymic T cells, cross-presentation of peptides<br />
263<br />
thymidine kinases of Herpes Simplex virus<br />
(HSV-tk) 304ff.
Change language